
    
      This clinical trial is a multi-center, randomized, controlled, open label, pilot study,
      lasting 6 months.

      A target number of seventy individuals with hypertension meeting inclusion and exclusion
      criteria, assessed at enrollment, and which have signed the informed consent, will be
      recruited.
    
  